NCT04735042View on ClinicalTrials.gov

SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

October 7, 2020

Primary Completion Date

October 7, 2021

Study Completion Date

April 7, 2022

Conditions
Type 2 DiabetesUrinary Tract Infections
Interventions
DRUG

Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill

association between SGLT2-inhibitor and DPP4-inhibitor

DRUG

Empagliflozin or Dapagliflozin Pill

SGLT2-inhibitor: diabetic oral drug with diuretic properties.

Trial Locations (1)

56125

University of Pisa, Pisa

All Listed Sponsors
lead

University of Pisa

OTHER

NCT04735042 - SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections. | Biotech Hunter | Biotech Hunter